Home / Business and Economy / Pfizer's Metsera Acquisition Strengthens Obesity Treatment Offerings
Pfizer's Metsera Acquisition Strengthens Obesity Treatment Offerings
30 Sep, 2025
Summary
- Pfizer acquired Metsera, re-entering obesity treatment market
- Metsera brings promising long-acting GLP-1 and amylin agents
- Pfizer seen as undervalued growth stock by hedge funds
In September 2025, Pfizer Inc. made a strategic move to strengthen its position in the obesity treatment market by acquiring Metsera. This acquisition allows Pfizer to re-enter a segment it had previously exited, bringing with it a promising pipeline of long-acting GLP-1 and amylin agents. These new drugs are expected to compete well against current market leaders like Eli Lilly and Novo Nordisk.
The deal also includes contingent value rights, which reduce Pfizer's risk while enhancing its market position. Analyst Evan Seigerman from BMO Capital has maintained a Buy rating on Pfizer, with a price target of $30, citing the company's attractive valuation compared to its peers in the sector. Seigerman believes Pfizer's growth prospects, including the potential for revenue growth and margin improvement, are not yet fully recognized by the market.
Pfizer is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines. While the company's recent acquisition and growth potential are promising, some AI stocks may offer even greater upside potential and lower downside risk for investors.
